Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Ruochen Zang,James Brett Case,Eylan Yutuc,Xiucui Ma,Sheng Shen,Maria Florencia Gomez Castro,Zhuoming Liu,Qiru Zeng,Haiyan Zhao,Juhee Son,Paul W. Rothlauf,Alex J. B. Kreutzberger,Gaopeng Hou,Hu Zhang,Sayantan Bose,Xin Wang,Michael D. Vahey,Kartik Mani,William J. Griffiths,Tom Kirchhausen,Daved H. Fremont,Haitao Guo,Abhinav Diwan,Yuqin Wang,Michael S. Diamond,Sean P. J. Whelan,Siyuan Ding
DOI: https://doi.org/10.1073/pnas.2012197117
IF: 11.1
2020-11-25
Proceedings of the National Academy of Sciences
Abstract:Significance The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms. Thus, there is an urgent need to identify effective antivirals as countermeasures before safe and effective vaccines are developed, tested, and then produced on a large scale. Our approach is to harness the germline-encoded interferon antiviral response to inhibit SARS-CoV-2 replication thereby limiting its pathogenicity.
multidisciplinary sciences